Alectinib

• Mechanism of Action
• Anaplastic lymphoma kinase (ALK) is a novel receptor tyrosine kinase associated with ~60% of anaplastic large-cell lymphoma and ~5% of non-small cell lung cancer. Inhibition of these receptors interrupts downstream signalling pathways and suppresses cellular proliferation.

Clinical Use

• • Indication
  • ALK-positive locally advanced or metastatic non small cell lung cancer (NSCLC).
• • Adverse Effects